The United Kingdom and the United States have concluded a landmark bilateral deal that will maintain zero levies on British pharmaceutical shipments entering the US market.
The Terms of the Pact
As part of the deal, the UK has committed to increase expenditure on medicines through the National Health Service (NHS). This move secures that import taxes on these key products will remain at nothing for a period of three years.
This agreement comes after recent statements to significantly raise duties on patented pharmaceutical imports, with figures floated as high as double the cost.
"This arrangement with the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes much-needed fairness to American-British pharmaceutical trade," a release said.
Economic Impact
Drugs are one of the the United Kingdom's largest goods shipped to the United States, which is by far the largest destination for leading companies like GSK and AstraZeneca.
Trade data reveal that in the year to the end of last September, the UK sold medicines totaling billions to the US. This figure represented a significant portion of all goods exports in that period.
"This deal secures work, increases funding and facilitates the UK to establish itself as a worldwide center for medical research," a minister remarked.
Specific NHS Changes
The pact includes several notable commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to raise overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must return to the NHS to prevent overspending will be capped at 15%. Last year, rebates topped twenty percent.
Recent Tensions
This agreement takes place against a protracted dispute between the sector and the UK government over medicine costs and NHS adoption.
The disagreement were heightened by claims that US customers were paying significantly more for the identical medicines than patients in the other developed nations.
Recently, several large pharmaceutical investments in the UK have been delayed or cancelled, while major expansions have been announced toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a share of its total funding over the previous ten-year period.
